Derived from Dal Porto; Kurosaki; Mackay and Schneider.1-3
B-cell activating factor (BAFF) is a member of the TNF family and has been shown to be an important survival factor for peripheral B cells. BAFF has been implicated in conferring a survival advantage to B-cell malignancies, such as multiple myeloma.4
Tabalumab (LY2127399) is a fully human monoclonal antibody that was designed to have neutralizing activity against both membrane-bound and soluble BAFF.5
Tabalumab is being investigated in clinical trials for the treatment of multiple myeloma.